Literature DB >> 27226191

Chemokine RANTES is increased at early stages of coronary artery disease.

J Podolec1, G Kopec2, L Niewiara3, M Komar2, B Guzik3, K Bartus4, L Tomkiewicz-Pajak2, T J Guzik5, W Plazak2, K Zmudka3.   

Abstract

Cardiovascular diseases, and in particular coronary artery disease (CAD), are the leading causes of death in Europe and represent around 50% of overall mortality. Numerous cardiovascular markers have been proposed in relation to cardiovascular risk prediction, in relation to cardiac and vascular and cerebral events. Chemokines which regulate immune cell vascular chemotaxis, including CCL5/RANTES are points of great interest. We hypothesized that chemokine RANTES level measured in peripheral blood may be associated with severity of atherosclerosis in patients with stable angina undergoing coronary angiography. RANTES and interleukin 18 (IL-18) levels were measured by ELISA. Classical and novel cardiovascular risk factors like brachial flow mediated dilation and intima-media thickness were analyzed in the context of chemokine levels and severity of atherosclerosis. Study included 62 consecutive patients with coronary atherosclerosis demonstrated by coronary angiography, (mean age 59.3 years (S.D. = 7.4)), divided into two groups: group I with lower severity of atherosclerosis, (n = 45) and group 2 with severe CAD (n = 17) based on coronary angiography. Groups were well balanced for classic risk factors for atherosclerosis. Mean RANTES level were significantly higher in patients in group I (67.9 ng/ml, S.E.M. = 3.97) than in group II (50.5 ng/ml, S.E.M. = 7.49; P = 0.03). In contrast, IL-18 levels were similar in both groups (255 pg/ml in group I and 315 pg/ml, S.E.M. = 40.91 in group I, P = 0.12), as well as hsCRP concentration (3.45 S.E.M. = 2.66 ng/ml and 4.69 ng/ml S.E.M.= 1.64 ng/ml respectively; P = 0.47). Flow-mediated dilatation (FMD) values have been significantly lower in group II than in group I (6.31; S.E.M. = 0.61; vs 4.41; S.E.M. = 0,56, respectively, P = 0.026), while nitroglycerine-mediated dilatation (NMD) did not differ, indicating more pronounced endothelial dysfunction. No significant correlations between chemokine RANTES levels and intima-media thickness (IMT), FMD measurements have been found in the total population studied. Chemokine RANTES level could become a useful marker of severity of coronary artery disease. Its lower levels were observed in patients with more diffuse disease. Elevated level of chemokine RANTES in patients with stable angina pectoris may evaluate patients to high risk group in plaque formation at early stages of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27226191      PMCID: PMC6281158     

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  33 in total

Review 1.  Clinical application of C-reactive protein for cardiovascular disease detection and prevention.

Authors:  Paul M Ridker
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

2.  Comparison of the efficiency of Na+/Ca2+ exchanger or Na+/H+ exchanger inhibition and their combination in reducing coronary reperfusion-induced arrhythmias.

Authors:  J Szepesi; K Acsai; Z Sebok; J Prorok; P Pollesello; J Levijoki; J Gy Papp; A Varro; A Toth
Journal:  J Physiol Pharmacol       Date:  2015-04       Impact factor: 3.011

3.  Association of the CCR5Δ32 polymorphism and its ligand RANTES-403G/A polymorphism with coronary artery disease: a meta-analysis.

Authors:  Lihan Wang; Xinyang Hu; Shoude Zhang; Xin Xu; Jianan Wang
Journal:  Thromb Res       Date:  2013-01-09       Impact factor: 3.944

4.  Serum profiles of C-C chemokines in acute myocardial infarction: possible implication in postinfarction left ventricular remodeling.

Authors:  John T Parissis; Stamatis Adamopoulos; Koula F Venetsanou; Dimitrios G Mentzikof; Spilios M Karas; Dimitrios Th Kremastinos
Journal:  J Interferon Cytokine Res       Date:  2002-02       Impact factor: 2.607

5.  Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6.

Authors:  Johannes Hulthe; William McPheat; Ann Samnegård; Per Tornvall; Anders Hamsten; Per Eriksson
Journal:  Atherosclerosis       Date:  2006-01-06       Impact factor: 5.162

6.  Common carotid intima-media thickness and risk of acute myocardial infarction: the role of lumen diameter.

Authors:  Michiel L Bots; Diederick E Grobbee; Albert Hofman; Jacqueline C M Witteman
Journal:  Stroke       Date:  2005-03-03       Impact factor: 7.914

7.  A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice.

Authors:  Vincent Braunersreuther; Sabine Steffens; Claire Arnaud; Graziano Pelli; Fabienne Burger; Amanda Proudfoot; François Mach
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-04-03       Impact factor: 8.311

Review 8.  New aspects of pathogenesis of atrial fibrillation: remodelling of intercalated discs.

Authors:  N Tribulova; T Egan Benova; B Szeiffova Bacova; C Viczenczova; M Barancik
Journal:  J Physiol Pharmacol       Date:  2015-10       Impact factor: 3.011

9.  European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).

Authors:  Joep Perk; Guy De Backer; Helmut Gohlke; Ian Graham; Zeljko Reiner; W M Monique Verschuren; Christian Albus; Pascale Benlian; Gudrun Boysen; Renata Cifkova; Christi Deaton; Shah Ebrahim; Miles Fisher; Giuseppe Germano; Richard Hobbs; Arno Hoes; Sehnaz Karadeniz; Alessandro Mezzani; Eva Prescott; Lars Ryden; Martin Scherer; Mikko Syvänne; Wilma J M Scholte Op Reimer; Christiaan Vrints; David Wood; Jose Luis Zamorano; Faiez Zannad
Journal:  Int J Behav Med       Date:  2012-12

10.  RANTES/CCL5 and risk for coronary events: results from the MONICA/KORA Augsburg case-cohort, Athero-Express and CARDIoGRAM studies.

Authors:  Christian Herder; Wouter Peeters; Thomas Illig; Jens Baumert; Dominique P V de Kleijn; Frans L Moll; Ulrike Poschen; Norman Klopp; Martina Müller-Nurasyid; Michael Roden; Michael Preuss; Mahir Karakas; Christa Meisinger; Barbara Thorand; Gerard Pasterkamp; Wolfgang Koenig; Themistocles L Assimes; Panos Deloukas; Jeanette Erdmann; Hilma Holm; Sekar Kathiresan; Inke R König; Ruth McPherson; Muredach P Reilly; Robert Roberts; Nilesh J Samani; Heribert Schunkert; Alexandre F R Stewart
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

View more
  13 in total

1.  CCR5 antagonist treatment inhibits vascular injury by regulating NADPH oxidase 1.

Authors:  Shubhnita Singh; Ariane Bruder-Nascimento; Eric J Belin de Chantemele; Thiago Bruder-Nascimento
Journal:  Biochem Pharmacol       Date:  2021-11-26       Impact factor: 5.858

Review 2.  Perivascular adipose tissue inflammation in vascular disease.

Authors:  Ryszard Nosalski; Tomasz J Guzik
Journal:  Br J Pharmacol       Date:  2017-02-09       Impact factor: 8.739

3.  Current advances in circulating inflammatory biomarkers in atherosclerosis and related cardio-cerebrovascular diseases.

Authors:  Jun-Xuan Lv; Qi Kong; Xin Ma
Journal:  Chronic Dis Transl Med       Date:  2017-11-26

Review 4.  The role of infiltrating immune cells in dysfunctional adipose tissue.

Authors:  Tomasz J Guzik; Dominik S Skiba; Rhian M Touyz; David G Harrison
Journal:  Cardiovasc Res       Date:  2017-07-01       Impact factor: 10.787

Review 5.  Epigenetics and Immunometabolism in Diabetes and Aging.

Authors:  Tomasz J Guzik; Francesco Cosentino
Journal:  Antioxid Redox Signal       Date:  2017-10-16       Impact factor: 8.401

6.  Clinical experience with 12-month follow-up in patients after implantation of a novel long-tapered sirolimus drug-eluting stent.

Authors:  Jakub Podolec; Maciej Skubera; Łukasz Niewiara; Mateusz Podolec; Piotr Pieniążek; Krzysztof Bartuś; Krzysztof Żmudka; Jacek Legutko
Journal:  Postepy Kardiol Interwencyjnej       Date:  2019-03-15       Impact factor: 1.426

7.  Factors Associated with RANTES Concentration in Cardiovascular Disease Patients.

Authors:  Olga M Koper-Lenkiewicz; Joanna Kamińska; Anna Lisowska; Anna Milewska; Tomasz Hirnle; Violetta Dymicka-Piekarska
Journal:  Biomed Res Int       Date:  2019-07-18       Impact factor: 3.411

8.  Serum protein signature of coronary artery disease in type 2 diabetes mellitus.

Authors:  Ramu Adela; Podduturu Naveen Chander Reddy; Tarini Shankar Ghosh; Suruchi Aggarwal; Amit Kumar Yadav; Bhabatosh Das; Sanjay K Banerjee
Journal:  J Transl Med       Date:  2019-01-24       Impact factor: 5.531

9.  Chemokine RANTES and IL-1β in mild therapeutic hypothermia-treated patients after out-of-hospital sudden cardiac arrest.

Authors:  Jakub Podolec; Aleksander Trąbka-Zawicki; Rafał Badacz; Mateusz Siedliński; Marek Tomala; Krzysztof Bartuś; Jacek Legutko; Tadeusz Przewłocki; Krzysztof Żmudka; Anna Kabłak-Ziembicka
Journal:  Postepy Kardiol Interwencyjnej       Date:  2019-03-15       Impact factor: 1.426

10.  Anti-atherosclerotic effect of the angiotensin 1-7 mimetic AVE0991 is mediated by inhibition of perivascular and plaque inflammation in early atherosclerosis.

Authors:  D S Skiba; R Nosalski; T P Mikolajczyk; M Siedlinski; F J Rios; A C Montezano; J Jawien; R Olszanecki; R Korbut; M Czesnikiewicz-Guzik; R M Touyz; T J Guzik
Journal:  Br J Pharmacol       Date:  2017-02-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.